Vanda Pharmaceuticals Raises 2026 Revenue Guidance on Strong Q1 Sales & New Product Launches

summarizeSummary

Vanda Pharmaceuticals reported Q1 2026 results, raising full-year revenue guidance to $240-$290 million driven by strong Fanapt sales and the launch of NEREUS™, alongside recent FDA approval for BYSANTI™.

check_boxKey Events

• Raised Full-Year 2026 Revenue Guidance

  Vanda Pharmaceuticals increased its full-year 2026 total revenue guidance to $240-$290 million, up from the prior range of $230-$260 million, incorporating $10-$30 million from the newly launched NEREUS™.

• Strong Q1 Product Sales & New Launch

  Total net product sales for Q1 2026 reached $51.7 million, a 3% increase year-over-year, with Fanapt® sales growing 26% to $29.6 million. The company also commercially launched NEREUS™ (tradipitant) for motion-induced vomiting via a direct-to-consumer platform.

• Key Regulatory Approvals & Pipeline Progress

  BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in February 2026. The Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis (GPP) was accepted for FDA review with a PDUFA target action date of December 12, 2026.

• Increased Net Loss Amidst Investments

  The company reported a net loss of $48.6 million ($0.82 diluted loss per share) in Q1 2026, compared to a net loss of $29.5 million in Q1 2025, reflecting continued investment in new product launches and pipeline advancement. Cash, cash equivalents, and marketable securities decreased by $61.5 million in Q1 2026 to $202.3 million.

auto_awesomeAnalysis

Vanda Pharmaceuticals reported a mixed first quarter, with a significantly increased net loss but also strong commercial execution and positive pipeline developments. The company raised its full-year 2026 revenue guidance to $240-$290 million, up from $230-$260 million, primarily driven by robust Fanapt sales growth and the successful launch of NEREUS™ (tradipitant) via a direct-to-consumer platform. Additionally, the FDA approval of BYSANTI™ (milsaperidone) in February and the BLA acceptance for imsidolimab for GPP with a PDUFA date in December 2026 highlight ongoing regulatory progress. While the net loss widened and cash decreased due to investments and a milestone payment, the raised guidance and new product commercialization efforts signal positive momentum and potential for future growth.